Stay updated with breaking news from Orpharma Pty Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The urea cycle disorder treatment market size is expected to grow by USD 235.5 million from 2022 to 2027. In addition, the momentum of the...
Segmented By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC...
According to a recent Future Market Insights analysis, the global hyperammonemia treatment market is anticipated to reach a valuation of US$ 1,318.05 Million in 2023 and US$ 2,100 Million by 2033, with a CAGR of 4.77%.The increased frequency of urea cycle diseases, as well as extensive research and development, are...
: The rising prevalence of urea cycle disorders is expected to increase the demand for treatment options for urea cycle disorders (UCD), which is expected to drive the growth of global urea cycle disorders treatment market during the forecast period. According to the Urea Cycle Disorders Consortium (UCDC), a part of the Rare Diseases Clinical Research Network (RDCRN), combined prevalence of urea cycle disorders is around 1 in 30,000 people in the U.S in 2017 Among regions, North America is expected to hold dominant position in the global urea cycle disorders treatment market during the forec...